BRAF and differentiated thyroid carcinoma: Compared to conventional PTC, columnar cell variant histology portents poor prognosis.40,41 As a result, we opted for use of vemurafenib over sorafenib (an Food and Drug Administration–approved drug for refractory advanced differentiated thyroid carcinoma) because of its potent BRAF signaling inhibition.